Pharmacological inhibition of C5aR1, using the nonpeptide inhibitor avacopan, reduced mitochondrial fission and podocyte damage, identifying dysfunction in mitochondrial dynamics and C5aR1 signaling as key drivers of LN pathology (85). The gene discussed is C5AR1; the disease is lobular neoplasia.